echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Late mortality and life expectancy of Allo-HSCT recipients in the past 40 years

    Late mortality and life expectancy of Allo-HSCT recipients in the past 40 years

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only curable treatment option for patients with hematological malignancies and some other life-threatening diseases.
    An estimated 10,000 patients in the United States receive Allo-HSCT each year
    .

    In the past 40 years, clinical practice of Allo-HSCT has undergone significant changes, including the use of Allo-HSCT for older patients; the use of alternative stem cell sources, such as peripheral blood stem cells (PBSCs) and cord blood; and the use of non-clear Medullary or reduced intensity pretreatment
    .

    Thanks to improvements in supportive care and management strategies for acute graft-versus-host disease (aGVHD), early transplant-related mortality has been significantly reduced, and the number of transplant survivors has increased
    .

    However, the long-term side effects of Allo-HSCT recipients such as secondary malignant tumors (SMN) and cardiovascular diseases (CVD) are worthy of attention
    .

    Based on this, some researchers have carried out a blood or bone marrow transplant survivor study (BMTSS) to analyze the cumulative impact of long-term complications and early mortality of Allo-HSCT recipients on life expectancy
    .

    Research Method BMTSS is a cohort study designed to examine the long-term outcome of patients who survived ≥ 2 years after Allo-HSCT at the University of Minnesota or the University of Alabama at Birmingham between January 1, 1974 and December 31, 2014
    .

    The cause of death that matches the pre-transplant diagnosis is classified as recurrence-related mortality (RRM)
    .

    All other causes of death are classified as non-relapse-related mortality (NRM)
    .

    Deaths caused by malignant diseases that are different from the pre-transplant diagnosis are classified as SMN-related
    .

    Deaths due to heart failure, coronary artery disease, arrhythmia, stroke, or other cardiovascular causes are classified as CVD-related
    .

    Deaths due to sepsis or other causes of infection are classified as infection-related
    .

    The researchers studied the trends of all-cause mortality and cause-specific mortality of recipients in three Allo-HSCT periods (1974-1989; 1990-2004; and 2005-2014) based on changes in transplant practice
    .

    Study results Patient characteristics: Overall, 4741 patients received Allo-HSCT between 1974 and 2014, and the survival time was ≥2 years
    .

    The median age of patients receiving Allo-HSCTBMT from 2005 to 2014 was 33 years
    .

    The median follow-up time after Allo-HSCT was 12 years
    .

    Acute myeloid leukemia (AML) is the most common indication (26.
    3%) of Allo-HSCT.
    Among them, 59.
    2% of patients received transplantation from a related donor, and 47.
    5% of patients' stem cells were derived from bone marrow
    .

    In the three periods, the median age of Allo-HSCT recipients showed an increasing trend (from 19.
    5 years to 43.
    0 years), receiving Allo-HSCT from unrelated donors (from 4.
    8% to 55.
    7%) and the high-risk subgroup receiving Allo-HSCT The proportion of patients (from 17.
    9% to 33.
    6%) is also increasing
    .

    In addition, the proportion of patients receiving systemic radiotherapy (TBI) (from 75.
    6% to 51.
    1%), myeloablative pretreatment (from 84.
    2% to 36.
    3%), and bone marrow-derived stem cells (from 99.
    8% to 20.
    5%) showed a downward trend; The incidence of chronic GVHD (cGVHD) increased (from 41.
    6% to 49.
    0%) (Table 1)
    .

    Table 1: Baseline characteristics of patients.
    Mortality and life expectancy: The risk of all-cause death in this cohort is 8.
    8 times higher than that of the general population (95% CI, 8.
    4-9.
    3)
    .

    The relative mortality rate was highest 2-5 years after Allo-HSCT (SMR, 34.
    3; 95% CI, 31.
    7-36.
    9), and then declined, but 30 years or more after Allo-HSCT was still significantly higher than the general population (SMR , 5.
    4; 95% CI, 4.
    0-7.
    1)
    .

    Over time, the relative mortality of patients after Allo-HSCT showed a downward trend, from 1974-1989 (SMR, 23.
    4) to 2005-2014 (SMR, 5.
    8) (P<0.
    001)
    .

    The 2-35-year mortality rate after Allo-HSCT exceeded the expected population mortality rate, showing a U-shaped curve, with the shortest follow-up time (2 years after transplantation: 39.
    4 deaths/1000 person-years) and the longest follow-up time (transplantation In the next 35 years: 31.
    0 deaths/1000 person-years), the difference in the expected mortality of individuals is even greater
    .

    The mortality of patients after Allo-HSCT increases with age, and the mortality at all ages is higher than the expected mortality in the general population
    .

    In an analysis limited to a 10-year follow-up, the number of years of life lost for Allo-HSCT recipients in the three periods showed a downward trend (from 9.
    9 years to 4.
    2 years) (Table 2)
    .

    Table 2: Multivariate analysis of all-cause mortality risk factors.
    Risk of late death: The 30-year overall survival (OS) rate of the entire cohort was 57.
    8% (52.
    5% to 80.
    6%); 10-year all-cause late mortality related risk Factors include older age at Allo-HSCT, male, high-risk disease, use of PBSCs as a source of stem cells, and cGVHD history (Table 2)
    .

    After adjusting for all relevant demographic and clinical variables, it was found that within 3 periods, the HR of 10-year all-cause mortality showed a decreasing trend (P<0.
    001) (Figure 1, Table 2)
    .

    A stratified analysis based on age (<18, 18-45 and >45 years) at Allo-HSCT showed that only in individuals aged <18 years of age who received transplantation, the reduction in late mortality according to the age of transplantation was statistically significant (P <0.
    001) (Figure 2A); analysis stratified by stem cell source showed that individuals who received only bone marrow-derived stem cells had a statistically significant decrease in the late mortality rate during the transplant era (P<0.
    001) (Figure 2B)
    .

    Figure 1: The trend of all-cause and cause-specific late death risks in Allo-HSCT recipients in different transplant eras.
    Figure 2: The OS status of Allo-HSCT recipients in different transplant eras.
    The risk of death from specific causes in allo-HSCT recipients: 1175 of the 1409 patients who died ( 83.
    4%) withdrew due to death, including RRM (473 cases [40.
    3%]), NRM (675 cases [57.
    4%]) and external causes (27 cases [2.
    3%])
    .

    The 30-year cumulative incidence of RRM was 12.
    2% (95% CI, 11.
    0%-13.
    4%) (Figure 3A), and NRM was 22.
    3% (95% CI, 20.
    4%-24.
    3%) (Figure 3B)
    .

    Figure 3: Conclusion of the study on cumulative mortality of Allo-HSCT recipients.
    This cohort study showed that the late mortality of Allo-HSCT recipients has declined in the past 40 years; however, compared with the general population in the United States, life expectancy has not Recover to the expected speed
    .

    In addition, the reduction in the risk of late death appears to be limited to patients who received transplants at a younger age or patients who received bone marrow stem cells
    .

    Efforts to reduce disease recurrence, infection, SMN, CVD and lung diseases may have a positive effect on improving the prognosis of this population
    .

    References: Smita Bhatia, Chen Dai, Wendy Landier, et al.
    Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.
    JAMA Oncol.
    2021 Sep 9.
    Read the original ", we make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.